Bristol Myers Squibb Company
NEWS
Bristol Myers Squibb released new data from two clinical trials of Opdivo plus Yervoy-based combinations in non-small cell lung cancer and updated results from the KarMMa trial of ide-cel for multiple myeloma being developed with bluebird bio.
This morning, the companies announced the regulatory agency issued a Refusal to File letter regarding the BLA for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pretreated relapsed and refractory multiple myeloma.
Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here’s a look at what’s on the schedule for the next two weeks.
The CD19-directed chimeric antigen receptor (CAR) T cell therapy is a treatment for adults with relapsed or refractory large B-cell lymphoma after at least two prior therapies.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
BMS and Exelixis Eye Potential Approval of RCC Combination Drug Following Positive Phase III Results
This morning, the two companies announced the positive topline results from the pivotal Phase III CheckMate -9ER study in previously untreated patients with renal cell carcinoma.
Bristol Myers Squibb is prepared for an additional windfall of cash after a judge boosted the damages the company is due from Gilead Sciences over a patent infringement regarding the technology related to a novel cancer therapy.
As the biopharma industry responds to the COVID-19 pandemic, some of the area’s companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here’s a look.
Here’s a look at the next two target action dates on the calendar for early April.
JOBS
IN THE PRESS